Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. - Wikidata - thesis-toulmin - TriplyDB

Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy.

Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy.

http://www.wikidata.org/entity/Q37092766

about

COA6 is a mitochondrial complex IV assembly factor critical for biogenesis of mtDNA-encoded COX2 The Role of G-Protein-Coupled Receptor Proteolysis Site Cleavage of Polycystin-1 in Renal Physiology and Polycystic Kidney Disease Kidney disease: new technologies translate mechanisms to cure Autophagy and regulation of cilia function and assembly Systems biology of polycystic kidney disease: a critical review biosigner: A New Method for the Discovery of Significant Molecular Signatures from Omics Data.The centrosomal OFD1 protein interacts with the translation machinery and regulates the synthesis of specific targets.Murine Models of Polycystic Kidney Disease.The prevalence and epidemiology of genetic renal disease amongst adults with chronic kidney disease in Australia.Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease.ADAM17 promotes proliferation of collecting duct kidney epithelial cells through ERK activation and increased glycolysis in polycystic kidney disease.Tumor bioenergetics: an emerging avenue for cancer metabolism targeted therapy Polycystic kidney disease and cancer after renal transplantation.Food Restriction Ameliorates the Development of Polycystic Kidney Disease.Molecular pathways and therapies in autosomal-dominant polycystic kidney disease Metabolomics for Biomarker Discovery: Moving to the Clinic Metabolomics and renal disease.Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease Inhibition of Aerobic Glycolysis Attenuates Disease Progression in Polycystic Kidney Disease.Vasopressin and disruption of calcium signalling in polycystic kidney disease.The Future of Polycystic Kidney Disease Research--As Seen By the 12 Kaplan Awardees.The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate.Regulation of Polycystin-1 Function by Calmodulin Binding.Combined Deletion of Vhl and Kif3a Accelerates Renal Cyst Formation Preventing Allograft Rejection by Targeting Immune Metabolism.mTORC1-mediated inhibition of polycystin-1 expression drives renal cyst formation in tuberous sclerosis complex.Fatty Acid Oxidation is Impaired in An Orthologous Mouse Model of Autosomal Dominant Polycystic Kidney Disease.Fat Burning Problem in Cystic Kidneys: an Emerging Common Mechanism of Chronic Kidney Disease.A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease Novel application of complementary imaging techniques to examine in vivo glucose metabolism in the kidney mTORC1-Induced HK1-Dependent Glycolysis Regulates NLRP3 Inflammasome Activation.2-Deoxy-d-Glucose Ameliorates PKD Progression.Transcriptome analysis reveals manifold mechanisms of cyst development in ADPKD.The polycystins are modulated by cellular oxygen-sensing pathways and regulate mitochondrial function.Hypoxia-inducible factor-1α causes renal cyst expansion through calcium-activated chloride secretion.microRNA-17 family promotes polycystic kidney disease progression through modulation of mitochondrial metabolism Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.The hallmarks of cancer: relevance to the pathogenesis of polycystic kidney disease.Autophagy in renal diseases.Metformin Inhibits Cyst Formation in a Zebrafish Model of Polycystin-2 Deficiency.

P2860

Q24338334-74A38791-3F83-4112-9998-1BC177748207 Q26775090-A3963D01-9470-4A88-9C74-F459EF011BB0 Q26825227-DD86A677-BC09-4929-8155-ADF24B39B31F Q26865107-761E9DF3-B95A-490B-821F-406FD561ED84 Q28081359-EFD13594-8331-4044-8BB3-13DED145371D Q31116678-CA1EA51F-FC21-474B-9E57-598ACA16A51C Q33682032-161B8AF6-B3D4-45E0-BC63-AF81C86C0024 Q33856965-E2290751-73C5-436D-B71D-D5DD70348B7D Q33858105-34C4646C-0495-477D-81BC-C683AC610D2C Q33872509-C28B0D40-09B6-4B80-B625-DEC3F65BC203 Q34131062-6DFA4949-0F86-4BE5-AAAB-3174597AC133 Q34179999-76838EF5-6578-426C-BD6F-9C6909CCB859 Q34260089-4F86BF02-E928-4E18-BEC4-DD5DD20B338F Q34500619-5429B200-1250-4E80-B10F-A49A55289C65 Q35578646-A2C42198-C044-47D6-B7C3-08064696A670 Q35674401-4662F021-BBEE-4AAA-8FBD-B26DFD57E862 Q35778649-5EBD24E4-0DFE-4A6E-82EC-086E528BB9F8 Q35836161-C19CAA85-530F-4200-B6E3-6E0A496BF8C5 Q35890367-6E0F467C-ECA4-44B9-97E4-17D5168D22A2 Q35962991-3055D3A5-63EB-41C7-9B45-A86697EA701C Q36003176-3CF091CD-9175-4C28-B142-884D299F99BD Q36066391-6C201C0E-B997-4D57-B341-389535E5EFEA Q36113034-EE85926D-F64A-4752-9FDD-DE275F1D366D Q36223330-5F72E72C-FD39-4EBB-9711-C3DFD20D1D06 Q36225691-40DD7434-AFF0-47DD-984D-13D3B17A3A0D Q36651027-4B947F82-CA64-421B-901E-933F6ECB472D Q36753925-29F104BF-0551-42FC-A54C-7F815E42E74A Q36754147-66F2ED46-47C1-4E4F-B3AE-D6B80E6A7106 Q36810726-184CF0D2-7B01-4F23-8456-D1C8A2B52F83 Q36810731-A15A6CD3-7ABE-4E11-BA9E-CA7DDEBF7CC2 Q36874412-41D8DF19-34FB-45AF-99D9-CC01E24F97A7 Q37051989-61285F0C-2E53-48BD-8ED4-19D96104A8DB Q37426288-9CC2479A-A3AC-4461-9812-00008BB9BB3F Q37583250-66C2ED79-86EC-41D5-B138-B306204A00A7 Q37604709-29CC5802-1B7A-4216-B3DA-1E14E28F0479 Q37651950-7D683760-DDC4-4069-A57B-ABFD50D56C3F Q38171193-85996E9E-535F-40C8-AFD1-04925E7CDF80 Q38419495-481031A7-A229-4533-8E28-C61D0B3DC91C Q38542636-334EC58D-50CB-4BF3-9C27-69D4DE9DAE37 Q38645850-69F2B659-14D4-489E-8A92-C2174BEC6CDA

P2860

Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy.

http://www.wikidata.org/entity/Q37092766

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 24 March 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Defective glucose metabolism i ...... es a new therapeutic strategy.

@en

Defective glucose metabolism i ...... es a new therapeutic strategy.

@nl

type

label

Defective glucose metabolism i ...... es a new therapeutic strategy.

@en

Defective glucose metabolism i ...... es a new therapeutic strategy.

@nl

prefLabel

Defective glucose metabolism i ...... es a new therapeutic strategy.

@en

Defective glucose metabolism i ...... es a new therapeutic strategy.

@nl

P1433

Q37092766-EF1B5161-7789-4AF0-8610-6FE8F5EFAC5C

P1476

Q37092766-16CB3E2F-0BF2-4F1D-944F-F8622FCA88FD

P2093

Q37092766-0ACB9107-4877-41A3-9353-F5638A8ECAC9

Q37092766-0F2ED26B-5805-48B3-A91B-C664B8BC8140

Q37092766-2AF74859-D08A-488D-8864-BA51FA9228D3

Q37092766-37CF1331-A3E1-4663-8C2D-F38BBBD48875

Q37092766-56B7D46B-CA19-4032-B56E-DDE5E1C4DE17

Q37092766-7CD11AF0-41FE-4BAF-A537-6FD1C51BB1DF

Q37092766-B91D8363-F676-4C9D-ABB7-E3805926653F

Q37092766-C7B251FE-4122-4962-855D-D4B7302D1016

Q37092766-E7F36F44-8328-4670-9842-B1FDAF2D4451

P2860

Q37092766-1727E94F-709D-4562-BFF6-CA5D75A0B4DF

Q37092766-3A43E20A-8CD3-47F2-BFCD-97A58AC97501

Q37092766-40311793-4D19-4B73-9604-27E522EF6047

Q37092766-44D34582-03E0-4AED-A711-1D86FA39E2FE

Q37092766-479E4885-ACF4-4428-921D-52AC71089405

Q37092766-493655D1-FE2F-437D-8FAF-CE75D0C07F3F

Q37092766-4D460B9B-7D1C-4133-9E5D-9DD9A284FB0D

Q37092766-5F7041C9-D64A-43A5-A7B1-A8C6F82BC746

Q37092766-61C4EC85-7999-4D23-9415-9AD12ACFB02F

Q37092766-6C34C791-FABC-48F7-8835-8E266B0BFA06

P2888

Q37092766-A127E100-6BFB-4EB6-BBD1-62A3A865533A

P304

Q37092766-8ADFB43F-AE93-4965-88F9-C5466343A6A3

P31

Q37092766-0E96EEA8-EB42-4735-96FF-5D37F8F16F08

P356

Q37092766-845988BE-ADC4-484A-9469-B596D76C9154

P407

Q37092766-26214B7C-C11A-45F1-9ECD-20ABDABD7E5D

P433

Q37092766-30B46D3A-7908-4ED3-8FC6-98F4C224FFF1

P478

Q37092766-22DFD141-8D37-4A86-B018-3E379148D695

P50

Q37092766-36FC791F-211A-4003-84EB-13FCCD0A72C2

Q37092766-3C8644BB-9145-4403-9842-AE22276D48E0

Q37092766-48B8942F-C0D2-47DD-AF55-4521B22F6890

Q37092766-A43DCF0E-EFAD-460B-95C1-0391EFD4E2C9

P577

Q37092766-E7D63B34-BE26-4D12-ABFA-05926BE22636

P5875

Q37092766-BD7D3A0F-6D0D-4AFC-BF97-CFAF0FB9F728

P698

Q37092766-3597744E-4961-4477-93A3-94852A687803

P921

Q37092766-FA060685-957C-4E04-9437-30F3F0F254C1

Q37092766-bf562dd5-c487-4daa-acf9-1d32424ae48a

P932

Q37092766-3BAFB82D-3D28-4393-81F6-0A74C22972BD

P356

P1433

Nature Medicine

P1476

Defective glucose metabolism i ...... ies a new therapeutic strategy

@en

P2093

Alessandra Boletta

http://www.w3.org/2001/XMLSchema#string

Feng Qian

http://www.w3.org/2001/XMLSchema#string

Hangxue Xu

http://www.w3.org/2001/XMLSchema#string

Monika Pema

http://www.w3.org/2001/XMLSchema#string

Silvia Mari

http://www.w3.org/2001/XMLSchema#string

Valeria Mannella

http://www.w3.org/2001/XMLSchema#string

Valeria Ulisse

http://www.w3.org/2001/XMLSchema#string

Xuewen W Song

http://www.w3.org/2001/XMLSchema#string

York Pei

http://www.w3.org/2001/XMLSchema#string

P2860

Nephrocystin-1 forms a complex with polycystin-1 via a polyproline motif/SH3 domain interaction and regulates the apoptotic response in mammals

Understanding the Warburg effect: the metabolic requirements of cell proliferation

Appetite for destruction: the inhibition of glycolysis as a therapy for tuberous sclerosis complex-related tumors

Activation of a metabolic gene regulatory network downstream of mTOR complex 1

Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study.

A novel mouse model reveals that polycystin-1 deficiency in ependyma and choroid plexus results in dysfunctional cilia and hydrocephalus.

Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.

Polycystic kidney disease.

Cyst formation and activation of the extracellular regulated kinase pathway after kidney specific inactivation of Pkd1.

Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis.

P2888

P304

488-493

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.3092

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Marco Chiaravalli

Giacomo Quilici

P577

2013-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236076146

http://www.w3.org/2001/XMLSchema#string

P698

23524344

http://www.w3.org/2001/XMLSchema#string

P921

P932

4944011

http://www.w3.org/2001/XMLSchema#string